A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours.

Abstract

2038 Background: BI 2536 is a novel highly potent and selective inhibitor of the serine-threonine kinase polo-like kinase 1 (Plk1), which is a key regulator of cell cycle progression. Objectives of this trial were the assessment of the maximum tolerated dose (MTD), overall safety, pharmacokinetics and efficacy of BI 2536 given intravenously. METHODS… (More)

Topics

Cite this paper

@article{Hofheinz2006API, title={A phase I repeated dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumours.}, author={Ralf-Dieter Hofheinz and A. Hochhaus and Salah-Eddin Al-Batran and Antonio Nanci and Volker L. Reichardt and Dirk Trommeshauser and M. Hoffmann and Martin Steegmaier and Gerd Munzert and Elizabeth L. Jaeger}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={2038} }